Clinical Infectious Diseases

Article	Citations
Withdrawn as duplicate: Cover image/text	777
Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines: Perceptions and Attitudes From the Food and Drug Administration Public Commentary	634
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Associated With an Indoor Music Event That Required Proof of Full Vaccination Against Coronavirus Disease 2019 (COVID-19) Prio	532
In the Literature	454
Reply to Focosi et al	426
Correction to: Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial	303
Acute Appendicitis of Unexpected Etiology	221
Correction to: Prevalence of Ocular Complications in Candidemia: Defining the “Battlefield”	202
Eyes Wide Shut: A Cohort Study Questioning the Role of Fundoscopy in Infective Endocarditis Diagnosis	200
Response to Rezahosseini and Barrella Harboe	170
Association of Virus Variation and Vaccination Status With Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection	167
Susceptibility to Human Immunodeficiency Virus Type 1 Acquisition Linked to Malaria Exposure: A Case-Control Study	147
Correction to: Severe Dysbiosis and Specific Haemophilus and Neisseria Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patie	143
Response to ‘Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome’	139
Integrating Human Immunodeficiency Virus–Specific Elements in the Treatment of Tobacco Dependence (ANRS 144 Inter-ACTIV)	139
Systematic Review of In Vitro Antimicrobial Susceptibility Testing for Bacillus anthracis, 1947–2019	130
Trends in Age-Related Health Outcomes in People with HIV in Spain, 2006–2023	128
Daily Second-generation Integrase Strand Inhibitors and Short-course Tuberculosis Preventive Therapy: What More Do We Need to Know?	128
Comparative Performance of Urine Lipoarabinomannan and Urine Xpert MTB/RIF Ultra for Diagnosing Tuberculosis in Adult Inpatients With HIV in East London, South Africa	121
Don’t Put Off Until Tomorrow What You Can Do Today: Hospital Admissions as an Opportunity to Treat Hepatitis C	121
Use of Carbon Dioxide Monitoring to Assess Ventilation at a National Infectious Diseases Conference	120
Diagnostic Uncertainties and Delayed Treatment Protocols Impact Efficacy of FMT for Clostridioides difficile Infection	119
Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort	118
Historical Advances in Clinical Trial Design and Expanding Representation as the New Frontier for Innovation	117
Case Investigation and Contact Tracing Efforts From Health Departments in the United States, November 2020 to December 2021	113

Population Mobility and Aging Accelerate the Transmission of Coronavirus Disease 2019 in the Deep South: A County-Level Longitudinal Analysis	112
Correction to: Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Val	110
Lessons I Learned from Our Soldier	106
Pre-exposure Prophylaxis for Transgender People: A Systematic Review	103
Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States	101
Correction to: Clinical Experience With Severe Acute Respiratory Syndrome Coronavirus 2–Related Illness in Children: Hospital Experience in Cape Town, South Africa	99
Considerations on the Associations Between Antiretroviral Regimen and Changes in Blood Pressure in the D2EFT Study	98
Point-of-care Ultrasound in Infectious Diseases: Current Insights and Future Perspectives	94
Viral Suppression Trajectories Destabilized After Coronavirus Disease 2019 Among US People With Human Immunodeficiency Virus: An Interrupted Time Series Analysis	94
Modeling Respiratory Syncytial Virus Adult Vaccination in the United States With a Dynamic Transmission Model	92
Because I Hope for Something Better	91
Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment	90
Influenza Hospitalization Burden by Subtype, Age, Comorbidity, and Vaccination Status: 2012–2013 to 2018–2019 Seasons, Quebec, Canada	87
How Public Health Surveillance Systems Can Contribute to Antimicrobial Resistance Prevention: The Massachusetts Experience	86
Redefining Complicated Coagulase-Negative Staphylococcal Bacteremia	86
Nocardia farcinica as a Potential Pathogen Associated With a Clinical Subtype of Kikuchi–Fujimoto Disease	85
Characterizing the Rise of Disseminated Gonococcal Infections in California, July 2020–July 2021	83
Oral Antibiotics for Treatment of Gram-Negative Bacteremia in Solid Organ Transplant Recipients: A Propensity Score Weighted Retrospective Observational Study	82
How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus–Associated Cryptococcal Meningitis to High-Income Settings?	82
Enhanced Tuberculosis Diagnosis With Computer-aided Chest X-ray and Urine Lipoarabinomannan in Adults With HIV Admitted to Hospital (CASTLE Study): A Cluster Randomized Trial	82
How We Approach Suppressive Antibiotic Therapy Following Debridement, Antibiotics, and Implant Retention for Prosthetic Joint Infection	79
Chronic Aichi Virus Infection As a Cause of Long-Lasting Multiorgan Involvement in Patients With Primary Immune Deficiencies	77
Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial	75
Executive Summary: State-of-the-Art Review: State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms	75
Is 3 Really What We Need? Relative Effectiveness of Benzathine Penicillin G and Doxycycline Treatment Regimens for Late or Unknown Duration Syphilis in 6 US Jurisdictions, 2016–2021	72
2025 Content Collections from the IDSA Journals	71
Go V.I.R.A.L.: Social Media Engagement Strategies in Infectious Diseases	70
Accelerating Progress Towards the 2030 Neglected Tropical Diseases Targets: How Can Quantitative Modeling Support Programmatic Decisions?	70
International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness	69
Non- Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia	68
Collateral Benefits and Methodological Limits of Respiratory Syncytial Virus Immunization for Infant Otitis Media and Antibiotic Use	67
Hepatitis B reactivation following switch away from tenofovir-containing anti-retroviral therapy in people living with HIV: A case series and lessons for practice	66
Invasive Listeriosis in Southern Switzerland: A Local Problem That Is Actually Global	66
Predictors of Mortality of Streptococcal Bacteremia and the Role of Infectious Diseases Consultation: A Retrospective Cohort Study	66
Transmission of Mycobacterium tuberculosis to Healthcare Personnel Resulting From Contaminated Bone Graft Material, United States, June 2021–August 2022	65
Blood Culture Time to Positivity and Risk of Infective Endocarditis	65
A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptas	64
Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C	64
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity	64
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 201	62
Reduced Odds of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Vaccination Among New York City Adults, July 2021–November 2021	62
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Ill	62
Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis	62
Development of a Machine Learning Modeling Tool for Predicting HIV Incidence Using Public Health Data From a County in the Southern United States	61
Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination	61
Effectiveness of a Second Dose of an mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants	60
Are Contact Precautions “Essential” for the Prevention of Healthcare-associated Methicillin-Resistant Staphylococcus aureus?	60
Comparative Effectiveness of BNT162b2 and mRNA-1273 Booster Dose After BNT162b2 Primary Vaccination Against the Omicron Variants: A Retrospective Cohort Study Using Large-Scale Population-Based Regist	58
Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial	58
Personalized Antibiograms Using Multi-Task Machine Learning: Toward Mechanistic Understanding and Robust Calibration	56

Educational Impact of #IDJClub, a Twitter-Based Infectious Diseases Journal Club	56
COVID-19 Antiviral Medication Use Among Pregnant and Recently Pregnant US Outpatients	56
A National Retrospective Cohort Study Comparing the Effects of Cefepime Versus Piperacillin-Tazobactam on the Development of Severe Acute Kidney Injury in Patients With Septic Shock	56
Estimating Risk of Guillain-Barré Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis	56
The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination	55
You’ve Come a Long Way Baby—but Many Miles Left to Go	55
Diagnostic Yield of Repeat Blood Cultures and Risk Factors for Bloodstream Infection in Persistent Febrile Neutropenia	55
Epigenetic Age Acceleration Markers Are Associated With Physiologic Frailty and All-Cause Mortality in People With Human Immunodeficiency Virus	54
Clinical Presentation, Antimicrobial Resistance, and Treatment Outcomes of Aeromonas Human Infections: A 14-Year Retrospective Study and Comparative Genomics of 2 Isolates From Fatal Cases	54
Revisiting REVISIT: The Case for Ceftazidime/Avibactam Plus Aztreonam	54
A Point-of-Care Prediction Tool for Recurrent Tuberculosis	54
T-SPOT.TB Reactivity in Southern African Children With and Without in Utero Human Immunodeficiency Virus Exposure	53
Remdesivir Effectiveness in Reducing the Risk of 30-Day Readmission in Vulnerable Patients Hospitalized for COVID-19: A Retrospective US Cohort Study Using Propensity Scores	53
CD4/CD8 Ratio During Human Immunodeficiency Virus Treatment: Time for Routine Monitoring?	52
Two for the Price of One: Can Maternal Influenza Immunization Protect Infants Against Influenza and RSV?	52
Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study	52
IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19 Infections in Immunocompromised Patients	52
State-of-the-Art Review: Neurosyphilis	52
Post-artesunate Delayed Hemolysis in Patients With Severe Malaria in the United States—April 2019 Through July 2021	52
Does “Toxoplasma Abscess” Properly Describe Brain Lesions Caused by Toxoplasma gondii?	51
Zinc and Coronavirus Disease 2019	51
2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Staphylococcus aureus Bacteremia: Do We Already Know Enough?	51
Correction to: Higher Plasma Viremia in the Febrile Phase Is Associated With Adverse Dengue Outcomes Irrespective of Infecting Serotype or Host Immune Status: An Analysis of 5642 Vietnamese Cases	51
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial	51
Comment on Parameswaran et al's “Increased Stroke Risk Following Herpes Zoster Infection and Protection With Zoster Vaccine”	50
Correction to: Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination	50
Correction to: Coronavirus Disease 2019 Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study	50
High Time for Higher-Dose Rifampin	49
Maternal and Perinatal Outcomes Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Pregnancy, Florida, 2020–2021: A Retrospective Cohort Study	49
Regional and National Trends in Consumption of Antimicrobials in Pakistan; Pre and Post-COVID (2019–2021)	49
Treatment Completion and Sustained Virologic Response in the Context of Hepatitis C Virus Elimination: Time to Let Go of the Reins?	49
Association of Immunodeficiency and Human Immunodeficiency Virus Viremia With Cervical Precancer and Cancer Risk Among Women With Human Immunodeficiency Virus in South Africa	48
Serum Neutralizing Antibody Titers 12 Months After Coronavirus Disease 2019 Messenger RNA Vaccination: Correlation to Clinical Variables in an Adult, US Population	48
Discordant Clinical and Microbiological Outcomes Are Associated With Late Clinical Relapse in Clinical Trials for Complicated Urinary Tract Infections	48
Total Antimicrobial Consumption in Doxycycline Postexposure Prophylaxis Cohorts and the Intensity of Screening for Bacterial Sexually Transmitted Infections	48
Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50–59 Years Compared to ≥60 Years of Age	48
Investigating Determinants of Pathogenicity of Carbapenemase–Producing Enterobacterales	47
Assessment of the Effectiveness of Omicron Transmission Mitigation Strategies for European Universities Using an Agent-Based Network Model	47
Advancing Access to Diagnostic Tools Essential for Universal Health Coverage and Antimicrobial Resistance Prevention: An Overview of Trials in Sub-Saharan Africa	47
Background HIV Incidence in PURPOSE 1 and 2 PrEP Trials	47
Clinical and Molecular Analyses of Recurrent Gram-Negative Bloodstream Infections	47
Correction to: Anogenital Human Papillomavirus (HPV) Infection, Seroprevalence, and Risk Factors for HPV Seropositivity Among Sexually Active Men Enrolled in a Global HPV Vaccine Trial	46
Maternal Antibody Response and Transplacental Transfer Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection or Vaccination in Pregnancy	46
In the Literature	46
Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial	46
Welcoming Discourse on the Approach for Gram-Negative Bacteremia and Candidemia in Cardiovascular Implantable Electronic Device Infections	46
Correction to: Transmission of Carbapenem-Resistant Enterobacterales in an Overcrowded Emergency Department: Controlling the Spread to the Hospital	46
Risk of Acute Myocardial Infarction Among Patients With Laboratory-Confirmed Invasive Pneumococcal Disease: A Self-Controlled Case Series Study	46
Maintaining the Utility of Coronavirus Disease 2019 Pandemic Severity Surveillance: Evaluation of Trends in Attributable Deaths and Development and Validation of a Measurement Tool	45
Cephalosporins Versus Non-cephalosporin Antibiotics for Perioperative Prophylaxis in Primary Arthroplasty: A Systematic Review and Meta-Analysis	45
A Systematic Review of Human Challenge Trials, Designs, and Safety	45
Limited Durability of Improvements in Infection Prevention and Control Practices Following Reactive Interventions Leaves Healthcare Facilities Vulnerable to Ebola Virus Transmission	45
Patterns in Prescribing and Dispensing Influenza Antivirals Among Adults With Influenza Presenting to Urgent Care and Emergency Department Settings: VISION Network, 2023–2024	45
The Promise and Peril of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibodies	44
Serum Ammonia Screening and Donor Mollicutes Detection for Hyperammonemia Syndrome Post–Lung Transplantation: A Prospective Observational Study	44
Patients Hospitalized With Coronavirus Disease 2019: A Diverse Population	44
Innovations in Career Development Through Mentoring in the VTEU/IDCRC Programs	44
A 25-Year-Old Man With Fever, Diarrhea, and Shock	44
Costs Attributable to Clostridioides difficile Infection Based on the Setting of Onset	44
Tuberculosis Treatment Outcomes in Brazil: Different Predictors for Each Type of Unsuccessful Outcome	44
Point-of-Care Urine Tenofovir Drug-Level Feedback Counseling Improves Long-Term PrEP Adherence for US MSM in Pilot RCT	43
Application of Pragmatic Criteria to Assessments of Frailty and Physical Function Among People With HIV	43
Positive Effects of Cognitive-Behavioral Therapy Targeting Severe Fatigue Following COVID-19 Are Sustained Up to 1 Year After Treatment	43
Impact of Discontinuation of Contact Precautions on Healthcare-associated ESBL-producing Escherichia coli in a Large Tertiary Care Hospital: An Interrupt	43
Rabies Despite Postexposure Prophylaxis in High-Burden Settings: Vaccine Failure or Gaps in Healthcare Delivery?	43
Considerations for the Use of Long-Acting and Extended-Release Agents During Pregnancy and Lactation	42
Clinical Validation of a Novel T-Cell Receptor Sequencing Assay for Identification of Recent or Prior Severe Acute Respiratory Syndrome Coronavirus 2 Infection	42
Acceptability of a Fentanyl Vaccine to Prevent Opioid Overdose and Need for Personalized Decision-Making	42
Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae : Review of the Literature	42
Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods	42
Programmatic Effectiveness of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India	42
Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine	42
Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee	42
Improving Sepsis Outcomes in the Era of Pay-for-Performance and Electronic Quality Measures: A Joint IDSA/ACEP/PIDS/SHEA/SHM/SIDP Position Paper	42
Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice	42
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions	41
CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study	41
Evaluation and Management of Diabetes-related Foot Infections	41
The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic	41
Pregnancy Outcomes in Multidrug-Resistant Tuberculosis in TB-PRACTECAL	41

Reported Tuberculosis Symptoms: An Inadequate Classifier of Disease State	41
Updated hepatitis D seroprevalence among HBsAg-positive persons aged ≥6 years in the United States, National Health and Nutrition Examination Survey, 2007‒2018	41
Herpes Zoster, Vaccine, and Stroke Risk	40
Non-actionable Results, Accuracy, and Effect of First- and Second-line Line Probe Assays for Diagnosing Drug-Resistant Tuberculosis, Including on Smear-Negative Specimens, in a High-Volume Laboratory	40
State-of-the-Art Review: Anal Cancer Screening in People With HIV	40
HIV/AIDS and COVID-19: Shared Lessons From 2 Pandemics	40
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study	40
Sociodemographic and Occupational Factors Associated With COVID-19 Vaccine and Influenza Vaccine Uptake Among Healthcare Workers, in Albania, 2022–2023: A Multicenter Study	40
Side-by-side Comparative Study of the Immunogenicity of the Intramuscular and Intradermal Rabies Post-exposure Prophylaxis Regimens in a Cohort of Suspected Rabies Virus Exposed Individuals	40
DOLCE: Sweet Success for Dolutegravir/Lamivudine?	40
High Human T-Cell Leukemia Virus Type 1c Proviral Loads Are Associated With Diabetes and Chronic Kidney Disease: Results of a Cross-Sectional Community Survey in Central Australia	39
Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Patients With Pneumonia: A Prospective Observational Study	39
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial	39
Cardiovascular Disease Risk in Low- and MIddle-income countries: better data for better evidence	39
Increase in False-Positive Fourth-Generation Human Immunodeficiency Virus Tests in Patients With Coronavirus Disease 2019	39
Central Nervous System Antimicrobial Exposure and Proposed Dosing for Anthrax Meningitis	39
Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19	39
Invisible Malarias	39
Correction to: Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis	38
Implementation of Diagnostic Stewardship to Improve Urinary Tract Infection Antibiotic Use Across 3 Medical Centers	38
Missed Opportunities for HIV and Syphilis Co-Testing in Emergency Departments	38
Outcomes associated with empiric azithromycin use among patients hospitalized with non-severe community-acquired pneumonia: emulation of a target trial	38
Comparative Outcomes of Candida auris Bloodstream Infections: A Multicenter Retrospective Case-Control Study	38
Beyond Burnout: The Power of Purpose, Partnership, and Serving Others	38
A Retrospective, Observational Study of 12 Cases of Expanded-Access Customized Phage Therapy: Production, Characteristics, and Clinical Outcomes	38
Measles Without Rash During Acute Febrile Illness Surveillance in Tanzania, 2023–2024	38
Clinical Impact of Pleural Fluid Streptococcus pneumoniae Polymerase Chain Reaction Testing in Children With Complicated Pneumonia	38
Management of Diarrhea in Young Children in Sub-Saharan Africa: Adherence to World Health Organization Recommendations During the Global Enteric Multisite Study (2007–2011) and the Vaccine Impact of D	37
We Didn’t Start the Fire	37
Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial	37
Cost-Effective Treatment of Clostridiodes difficile Infection	37
Assessment of an Infectious Disease eConsult Service at a Large Mid-Atlantic Healthcare System	37
Acute Unilateral Vision Loss in a Young Woman	37
Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine	36
Low CD4+ Cell Counts Linked to Mortality Rate After Sustained Virological Response: Evaluating Interaction With Liver Stiffness Versus the Fibrosis-4 Score	36
The Dynamic Impact of Community Social Vulnerability on COVID-19 Outcomes: A Census Tract-level Analysis of Fulton County, Georgia	36
Development and Clinical Evaluation of a Novel Talaromyces marneffei Mp1p Lateral Flow Assay for Rapid Diagnosis of Talaromycosis	36
Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases	36
Is Higher Adherence Required for Women Using Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Preexposure Prophylaxis?	36
The Who, What, When, and Where of Inpatient Direct Oral Penicillin Challenge—Implications for Health Services Implementation	36
Comparing Generative Artificial Intelligence vs Experts for Detection of Catheter-Associated Urinary Tract Infection	36
Applying Desirability of Outcome Ranking End Points	36
An Ensemble Framework for Projecting the Impact of Lymphatic Filariasis Interventions Across Sub-Saharan Africa at a Fine Spatial Scale	35
Collaborative Strategies for Antimicrobial Stewardship Programs: Navigating Financial and Regulatory Landscapes	35
Immunological Efficacy of Pneumococcal Vaccination Including the 13-Valent Pneumococcal Conjugate Vaccine in Adult Patients With Sickle Cell Disease: Results of the Randomized DREVAC Controlled Trial	35
Put the Fluoroquinolone Down and No One Gets Hurt	35
Fever and Extensive Blistering in a Patient With Atopic Dermatitis	35
Lung and Brain Abscesses in an Upper Extremity Allotransplantation Recipient	35
Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-Exposure Prophylaxis Against Coronavirus Disease 2019: A Population-Based Propensity-matched Cohort Study	35
Questions About the 2023 Infective Endocarditis Updated Criteria	35
Environmental Testing of Surfaces in the Room of a Patient With Mpox	35
Risk of Psychiatric Disorders, Use of Psychiatric Hospitals, and Receipt of Psychiatric Medication in Patients With Brain Abscess in Denmark	35
Cholesterol Contributes to Risk, Severity, and Machine Learning-Driven Diagnosis of Lyme Disease	34
Duration of Effective Tuberculosis Treatment, Not Acid-Fast Bacilli (AFB) Smear Status, as the Determinant for De-isolation in Community Settings	34
Association Between Clostridium innocuum and Antibiotic-Associated Diarrhea in Adults and Children: A Cross-sectional Study and Comparative Genomics Analysis	34
Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 From Adult Index Cases With and Without Human Immunodeficiency Virus in South Africa, 2020–2021: A Case-Ascertained, Prospecti	34
Impact of Clinician Feedback Reports on Antibiotic Use in Children Hospitalized With Community-acquired Pneumonia	34
Tuberculosis Infection Screening Recommendations for Targeted Immunotherapies: Comparison of US Prescribing Information, Clinical Resources, and Quality Measures	34
Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women Living With HIV	34
Correct Calculation of Confidence Interval for Proportion of Superior Comparisons Between Desirability of Outcome Ranking Scores	34
Effectiveness of Coronavirus Disease 2019 Vaccines Against Hospitalization and Death in Canada: A Multiprovincial, Test-Negative Design Study	34
Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis	34
Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)	34
Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults Who Had Previously Received a Meningococcal ACWY Vaccine: A Phase 3, Randomized	34
Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019	34
Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price	34
Antibiotic Indications and Appropriateness in the Pediatric Intensive Care Unit: A 10-Center Point Prevalence Study	34
Real World Virologic Outcomes in Patients With Elevated Body Mass Index Receiving Long Acting Cabotegravir/Rilpivirine	33
It Takes Two to Transplant	33
Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection	33
New Strategies for a Vexing Problem: Injectables to the Rescue for People With Multidrug-Resistant HIV	33
The Frequency and Incidence of QT Prolongation With Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country Multidrug-Resistant/Rifampicin-Resistant Tuberculosis Cohort	33
Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance	33
Vaccine-Preventable Disease Outbreaks Among Healthcare Workers: A Scoping Review	33
Performance of Diagnostic Algorithms in Patients With Invasive Pulmonary Aspergillosis	33
Pleural Empyema: Etiology and Pathogenesis	33
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083	33
HIV, HIV-Specific Factors, and Myocardial Disease in Women	33
Febrile Phase Soluble Urokinase Plasminogen Activator Receptor and Olfactomedin 4 as Prognostic Biomarkers for Severe Dengue in Adults	33
Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries	33
Reassessing the 2023 International Society for Cardiovascular Infectious Diseases Duke Clinical Criteria for Infective Endocarditis: Impact of Excluding Fever and Updating Diagnostic Definitions	33
Efficacy of Primaquine for the Radical Cure of Plasmodium vivax Malaria in Northeast Myanmar and the Impact of Cytochrome P450 2D6 Genotypes	32
Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study	32
The Performance of Computer-Aided Detection Digital Chest X-ray Reading Technologies for Triage of Active Tuberculosis Among Persons With a History of Previous Tuberculosis	32
Transmission Blocking Activity of Low-dose Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum	32
TheStaphylococcus aureusNetwork Adaptive Platform Trial Protocol: New Tools for an Old Foe	32
Comparison of Influenza and Coronavirus Disease 2019–Associated Hospitalizations Among Children Younger Than 18 Years Old in the United States: FluSurv-NET (October–April 2017–2021) and COVID-NET (Oct	32
Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine—An Approach for Clinical Management	32
Centering AIDS Drug Assistance Programs in the US HIV Response	32
HIV-2 EU—Supporting Standardized HIV-2 Drug Resistance Interpretation: An Update	32
A Human Immunodeficiency Virus Type 1 Risk Assessment Tool for Women Aged 15–49 Years in African Countries: A Pooled Analysis Across 15 Nationally Representative Surveys	32
Japanese Encephalitis Emergence in Australia: The Potential Population at Risk	32
Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Intravenous Human Immunoglobulins Neutralizes Omicron Subvariants BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/BA.5 for Treatment of Coronavirus Di	31
Duration of Replication-Competent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Shedding Among Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)	31
Reference Susceptibility Testing and Genomic Surveillance ofClostridioides difficile, United States, 2012–17	31